Skip to content
Blerp – Lifestyle
Author:
Classover Holdings Inc.
KIDZ AI Wins 2026 EdTechX Award and Unveils KIDZBot AI Robotics Platform
July 6, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
KIDZ AI Named Finalist at the 2026 EdTechX Awards as Company Advances AI-Native Education Operating System, Agent Workflows and Robotics Learning Platform
June 10, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 8, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
KIDZ AI Announces Reverse Stock Split
June 4, 2026
KIDZ AI Enters Strategic Collaboration With XuanYuan Technology to Expand AI Education Into Physical, Agent-Powered Learning Environments
June 3, 2026
KIDZ AI Announces Strategic Treasury Pivot to Hyperliquid Ecosystem and Yield-Bearing Stablecoin Strategies
June 2, 2026
1
2
3
4
Next Page
→